BMY reports early participation and pricing on multiple long-dated note tenders

Rhea-AI Filing Summary

Bristol Myers Squibb Company reported that it has announced early participation results, an amendment and early settlement for previously launched cash tender offers to purchase its outstanding notes. The company also disclosed the accepted amounts and pricing terms for these tender offers in a subsequent press release. These actions are governed by an Offer to Purchase dated November 3, 2025, which sets out the detailed terms and conditions and limits where the offers are valid.

Insights

Corporate finance analyst

Bristol Myers Squibb outlines early results and pricing for cash tender offers on several outstanding notes.

Bristol Myers Squibb describes progress on cash tender offers to purchase certain outstanding notes it previously issued. The company reports early participation results, an amendment and early settlement of these offers, indicating that some noteholders have already responded under the terms of an Offer to Purchase dated November 3, 2025. A follow-up press release provides the accepted amounts and pricing terms for the participating notes.

The notes listed on the exchange include series such as the 1.750% notes due 2035, 2.973% notes due 2030, 3.363% notes due 2033, 3.857% notes due 2038, 4.289% notes due 2045 and 4.581% notes due 2055. The cash tender offers relate to these types of instruments, but specific principal amounts and acceptance levels are contained in the attached press releases rather than in this summary.

Because the filing focuses on procedural updates—early participation, amendment, early settlement, and pricing disclosure—without quantifying the financial scale, its impact is primarily informational. Future company communications may provide more detail on how much of each note series is actually repurchased and any resulting changes to the debt profile.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

What did Bristol Myers Squibb (BMY) announce in this 8-K?

Bristol Myers Squibb announced early participation results, an amendment and early settlement of previously launched cash tender offers to purchase certain notes it has issued.

Which Bristol Myers Squibb securities are related to these tender offers?

The company lists multiple note series traded on the NYSE, including 1.750% notes due 2035, 2.973% notes due 2030, 3.363% notes due 2033, 3.857% notes due 2038, 4.289% notes due 2045 and 4.581% notes due 2055.

When did Bristol Myers Squibb release information on the tender offers?

A press release on November 17, 2025 announced early participation results, amendment and early settlement, and a November 18, 2025 press release detailed accepted amounts and pricing terms.

Where can investors find the detailed terms of Bristol Myers Squibb’s tender offers?

The detailed terms and conditions of the offers are set out in an Offer to Purchase dated November 3, 2025, as amended or supplemented from time to time.

Are the tender offers by Bristol Myers Squibb an offer to buy notes in all jurisdictions?

No. The company states that the offers do not constitute an offer to buy or sell notes in any jurisdiction where such an offer or solicitation is unlawful, and they are void where prohibited.

What exhibits are included with this Bristol Myers Squibb (BMY) 8-K filing?

The filing includes a November 17, 2025 press release as Exhibit 99.1, a November 18, 2025 press release as Exhibit 99.2, and the Inline XBRL cover page as Exhibit 104.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding 8-K Material Events →

Accepted by SEC EDGAR 11/18/2025 - 04:41 PM Learn about SEC filing dates

false0000014272NYSENYSENYSENYSENYSENYSENYSENYSE00000142722025-11-172025-11-170000014272bmy:Three857NotesDue2038Member2025-11-172025-11-170000014272bmy:Four581NotesDue2055Member2025-11-172025-11-170000014272bmy:Three363NotesDue2033Member2025-11-172025-11-170000014272bmy:Four289NotesDue2045Member2025-11-172025-11-170000014272us-gaap:CommonStockMember2025-11-172025-11-170000014272bmy:One750NotesDue2035Member2025-11-172025-11-170000014272bmy:CelgeneContingentValueRightsMember2025-11-172025-11-170000014272bmy:Two973NotesDue2030Member2025-11-172025-11-17

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 17, 2025

BRISTOL-MYERS SQUIBB COMPANY

(Exact name of registrant as specified in its charter)

Delaware	001-01136	22-0790350
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S Employer Identification No.)

Route 206 & Province Line Road

Princeton, New Jersey 08543

(Address of principal executive offices) (zip code)

Registrant’s telephone number, including area code: (609) 252-4621

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.10 Par Value		BMY		New York Stock Exchange
1.750% Notes due 2035		BMY35		New York Stock Exchange
Celgene Contingent Value Rights		CELG RT		New York Stock Exchange
2.973% Notes due 2030		BMY/30		New York Stock Exchange
3.363% Notes due 2033		BMY/33		New York Stock Exchange
3.857% Notes due 2038		BMY/38		New York Stock Exchange
4.289% Notes due 2045		BMY/45		New York Stock Exchange
4.581% Notes due 2055		BMY/55		New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On November 17, 2025, Bristol-Myers Squibb Company (“Bristol Myers Squibb”) issued a press release announcing the early participation results, amendment and early settlement of its previously announced cash tender offers (the “Offers”) to purchase notes issued by Bristol Myers Squibb.

On November 18, 2025, Bristol Myers Squibb also issued a press release announcing the accepted amounts and pricing terms of such previously announced Offers.

The Offers are subject to the terms and conditions described in the Offer to Purchase dated November 3, 2025 (as amended or supplemented from time to time), which sets forth a detailed description of the Offers.

Copies of the press releases are attached hereto as Exhibits 99.1 and 99.2 to this Current Report on Form 8-K and incorporated herein in their entirety.

This Current Report on Form 8-K (including the exhibits attached hereto) is neither an offer to purchase nor a solicitation of an offer to sell any securities. The Offers are made only by, and pursuant to the terms of, the Offer to Purchase. The Offers do not constitute an offer to buy or the solicitation of an offer to sell the notes described herein in any jurisdiction in which such offer or solicitation is unlawful. The Offers are void in all jurisdictions where they are prohibited.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

The following exhibits are included as part of this Current Report on Form 8-K:

Exhibit No.		Description
99.1		Press release of Bristol-Myers Squibb Company dated November 17, 2025.
99.2		Press release of Bristol-Myers Squibb Company dated November 18, 2025.
104		The cover page from this Current Report on Form 8-K formatted in Inline XBRL (included as Exhibit 101).

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: November 18, 2025
	BRISTOL-MYERS SQUIBB COMPANY
	By:	/s/ Amy Fallone
	Name:	Amy Fallone
	Title:	Senior Vice President and Corporate Secretary

 2